Trial Data On Obesity Drug Wegovy May Not Be Enough To Convince Payers

Data presented at a meeting of the American Heart Association on Saturday indicates cardiovascular protective benefits from taking the weight loss therapeutic Wegovy for a sub-population with preexisting cardiovascular disease. But the absolute risk reduction is quite small. Payers will take notice of this in addition to the timing…